CIDP (chronic inflammatory demyelinating polyneuropathy): trials for referral
50 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
CIDP (chronic inflammatory demyelinating polyneuropathy)·What we know·Glossary
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
50 trials shown
Phase 222 sites
RecruitingCanada, Colombia, United States
NCT06798012
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase23 sites
RecruitingGermany, United States
NCT07264426
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
argenx
Pre-treatment window Registry sentence: “Efgartigimod treatment-naïve at time of screening”
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 2/3119 sites
RecruitingArgentina, Australia, Canada, China, Colombia, Czechia
NCT05327114
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Janssen Research & Development, LLC
Pre-treatment window Registry sentence: “Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (\<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (\>) 20 mg/day and the participant is willing to taper to \<=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)”
Registry updated 3 Nov 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govPhase 3113 sites
RecruitingArgentina, Austria, Australia, Bulgaria, Brazil, Canada
NCT06920004
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
argenx
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 3175 sites
RecruitingArgentina, Australia, Belgium, Bulgaria, Brazil, China
NCT06858579
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
Pre-treatment window Registry sentence: “Treatment naïve with no history of prior treatment for CIDP.”
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingGermany
NCT07882797
Multimodal Characterization of Movement Trajectories in Chronic Inflammatory Demyelinating Polyneuropathy
Heinrich-Heine University, Duesseldorf
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 363 sites
By invitation onlyArgentina, Bulgaria, Brazil, Canada, Chile, China
NCT06859099
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
Sanofi
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 398 sites
RecruitingArgentina, Austria, Bulgaria, Brazil, China, Colombia
NCT07091630
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
argenx
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 18 sites
RecruitingUnited States
NCT06680037
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 3138 sites
RecruitingArgentina, Belgium, Brazil, Canada, Switzerland, China
NCT06290141
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
Registry updated 19 Oct 2026
Registry record: ClinicalTrials.govPhase 110 sites
RecruitingAustralia, Canada, United States
NCT07304154
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Kite, A Gilead Company
Registry updated 19 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingChina
NCT07022197
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Tianjin Medical University General Hospital
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govPhase 310 sites
RecruitingCzechia, Poland, Romania
2025-522165-30-00
A Phase III study to evaluate how the body processes Xembify in comparison to Gamunex-C and determine the safety and in people with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Grifols Therapeutics LLC
Registry updated 14 Oct 2026
Registry record: EU CTISPhase 315 sites
RecruitingCzechia, Poland, Romania, United States
NCT07540221
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Grifols Therapeutics LLC
Registry updated 9 Oct 2026
Registry record: ClinicalTrials.govNo phase26 sites
Not yet recruitingFrance
NCT07851844
Clinical, Electrophysiological and Genetic Characteristics of Hereditary and Inflammatory Polyneuropathies in France
Assistance Publique - Hôpitaux de Paris
Registry updated 1 Oct 2026
Registry record: ClinicalTrials.govPhase 2136 sites
RecruitingArgentina, Austria, Australia, Belgium, Bulgaria, Brazil
NCT07032662
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
Registry updated 30 Sept 2026
Registry record: ClinicalTrials.govPhase 35 sites
RecruitingUnited States
NCT06752356
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Kedrion S.p.A.
Registry updated 11 Sept 2026
Registry record: ClinicalTrials.govPhase 368 sites
RecruitingBelgium, Bulgaria, Germany, Denmark, Spain, France
2024-517529-26-00
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics Inc.
Pre-treatment window Registry sentence: “Treatment naïve with no history of prior treatment for CIDP.”
Registry updated 28 Aug 2026
Registry record: EU CTISPhase 36 sites
RecruitingUnited States
NCT04929236
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Octapharma
Registry updated 5 Aug 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingChina
NCT06502015
Biomarkers in Autoimmune Disease of Nervous System
Tongji Hospital
Registry updated 29 Jul 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT06968975
Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
Sanofi
Registry updated 24 Jul 2026
Registry record: ClinicalTrials.govPhase 1/20 sites
Not yet recruiting
NCT07696377
An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Zhongming Qiu
Registry updated 10 Jul 2026
Registry record: ClinicalTrials.govPhase 2/30 sites
Not yet recruiting
NCT07638566
A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
argenx
Registry updated 10 Jun 2026
Registry record: ClinicalTrials.govNo phase2 sites
RecruitingGermany
NCT07273903
Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices
Heinrich-Heine University, Duesseldorf
Registry updated 10 Jun 2026
Registry record: ClinicalTrials.govPhase 49 sites
RecruitingUnited States
NCT03684018
Two Dose Levels of Privigen in Pediatric CIDP
CSL Behring
Registry updated 1 Jun 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
RecruitingChina
NCT07337785
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Tongji Hospital
Registry updated 12 May 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingChina
NCT07526493
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Tongji Hospital
Registry updated 12 May 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingGermany
NCT04881682
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
University of Ulm
Registry updated 1 May 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT07478172
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
University of Missouri-Columbia
Registry updated 17 Mar 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingItaly
NCT07461896
Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Registry updated 10 Mar 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States21 open trials
- Germany17 open trials
- China13 open trials
- Italy11 open trials
- Poland11 open trials
- Denmark10 open trials
- France9 open trials
- Spain9 open trials
- Argentina8 open trials
- Czechia8 open trials
- Japan7 open trials
- United Kingdom7 open trials
- Canada6 open trials
- Greece6 open trials
- Romania6 open trials
- Netherlands6 open trials
- Colombia5 open trials
- South Korea5 open trials
- Bulgaria5 open trials
- Brazil5 open trials
- Belgium5 open trials
- Portugal4 open trials
- Mexico4 open trials
- Hungary4 open trials
- Serbia4 open trials
- Australia4 open trials
- Taiwan3 open trials
- Slovenia3 open trials
- Austria3 open trials
- Slovakia3 open trials
- Israel3 open trials
- Sweden3 open trials
- Estonia2 open trials
- Singapore2 open trials
- Norway2 open trials
- Latvia2 open trials
- North Macedonia1 open trials
- Malaysia1 open trials
- Thailand1 open trials
- Vietnam1 open trials
- Eswatini1 open trials
- Chile1 open trials
- Georgia1 open trials
- Moldova1 open trials
- Switzerland1 open trials
- Peru1 open trials
- Ireland1 open trials
- Croatia1 open trials
- Egypt1 open trials
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
0 trials · 4 publications · ROR
First Pavlov State Medical University of St. Petersburg
St Petersburg, Russia
0 trials · 2 publications · ROR
National Hospital for Neurology and Neurosurgery
London, United Kingdom
0 trials · 3 publications · ROR
Neurological Institute, Graduate School of Medical Sciences, Kyushu University
Fukuoka, Japan
0 trials · 3 publications · ROR
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom
1 trials · 2 publications · ROR
The University of Texas MD Anderson Cancer Center
Houston, United States
0 trials · 3 publications · ROR
The University of Texas Medical Branch at Galveston
Galveston, United States
0 trials · 5 publications · ROR
The University of Texas Southwestern Medical Center
Dallas, United States
0 trials · 4 publications · ROR
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom
0 trials · 3 publications · ROR
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
1 trials · 8 publications · ROR
University of North Carolina at Chapel Hill
Chapel Hill, United States
0 trials · 5 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
No registry change in the last 7 days.
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 3Ended 29 May 2026
Phase 2Ended 4 May 2026
Completed99 participants
2024-515386-34-00
Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP
Phase 2Ended 17 Apr 2026
Completed35 participants
2024-518364-12-00
A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP
Phase 2Ended 17 Apr 2026
Completed178 participants
2024-512646-42-00
Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP.
Phase 4Ended 19 Feb 2026
Completed23 participants
NCT06637072
A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
Phase 2Ended 1 Oct 2025
Completed98 participants
NCT04658472
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
No phaseEnded 1 Aug 2025
Phase 1Ended 14 Apr 2025
Completed9 participants
NCT07343310
A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP
No phaseEnded 30 Dec 2024
Completed20 participants
NCT04356781
Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing
No phaseEnded 16 Jul 2024
Completed46 participants
NCT05723848
Electronic Monitoring of Disease Activity in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
No phaseEnded 30 Apr 2024
No phaseEnded 19 Jan 2024
Early Phase 1Ended 18 Dec 2023
No phaseEnded 8 Dec 2023
Phase 3Ended 30 Nov 2023
Completed37 participants
NCT06325943
Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Not medical advice. fetched 4 Nov 2026